Omeros strikes $40M fundraising deal; Shionogi wins OK for new anti-drooling drug;

 @FierceBiotech: Top 5 Biotech VC Deals of 2010. Article  | Follow @FierceBiotech

 @JohnCFierce: New idea: Offer EMA-approved drugs in U.S., fostering regulatory competition. I'll expect this three days after hell freezes. Story | Follow @JohnCFierce

> Seattle-based Omeros has struck a deal to sell up to $40 million in shares to a single investor--Azimuth Opportunity. "This financing vehicle provides flexibility and potentially strengthens our position as we pursue strategic opportunities," says CEO Gregory Demopulos. Release

> The FDA has approved Shionogi's new drug to treat severe drooling in patients with neurological disorders. Report

> Aptuit and Siena Biotech announced a deal in which Siena will take a minority stake in Aptuit's Italian operations in Verona, Italy, while Aptuit becomes a provider of choice for Siena Biotech's development pipeline. Release

> Isis earned a $5 million milestone payment from GlaxoSmithKline related to their discovery deal. Isis will develop the drug to Phase II proof-of-concept, at which time GSK has the option to license it.  Release

> Anadys says that six of six patients in the ANA598 200 mg twice daily arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12.  Release

> SynCo Bio Partners has extended its collaboration with Versartis following the recent initiation of a Phase I clinical trial in type 2 diabetes mellitus patients with monthly dosing of VRS-859. Release

And Finally... A new study shows that a sleep disorder may be a sign of dementia or Parkinson's disease up to 50 years before the disorders are diagnosed. Release

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.